References
- Peyrin-Biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:870–879.
- Actis GC, Pellicano R, Ribaldone DG. A concise history of thiopurines for inflammatory bowel disease: from anecdotal reporting to treat-to-target algorithms. Rev Recent Clin Trials. 2019;14:4–9.
- Hirten RP, Iacucci M, Shah S, et al. Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. Clin Gastroenterol Hepatol. 2018;16:1374–1384.
- Afzali A, Chiorean M. Combination of biologic agents in the management of severe refractory Crohn’s disease: a case report of concomitant treatment with vedolizumab and adalimumab. Am J Gastroenterol. 2016;111:S823–S824.
- Fischer S, Rath T, Geppert C-I, et al. Long-term combination therapy with anti-TNF plus vedolizumab induces and maintains remission in therapy-refractory ulcerative colitis. Am J Gastroenterol. 2017;112:1621–1623.
- Roblin X, Paul S, Ben-Horin S. Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy. J Crohns Colitis. 2018;12:379–380.
- Buer LCT, Høivik ML, Warren DJ, et al. Combining anti-TNF-α and vedolizumab in the treatment of inflammatory bowel disease: a case series. Inflamm Bowel Dis. 2018;24:997–1004.
- Mao EJ, Lewin S, Terdiman JP, et al. Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics. BMJ Open Gastroenterol. 2018;5:e000243.
- Huff-Hardy K, Bedair M, Vazquez R, et al. Efficacy of combination vedolizumab and ustekinumab for refractory Crohnʼs disease. Inflamm Bowel Dis. 2017;23:E49.
- Liu EY, Loomes DE. Ustekinumab and vedolizumab dual biologic therapy in the treatment of Crohn’s disease. Case Rep Med. 2017;2017:1–2.
- Côté-Daigneault J, Bouin M, Lahaie R, et al. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J. 2015;3:419–428.
- Ribaldone D, Pellicano R, Actis G, et al. Pathogenesis of inflammatory bowel disease: basic science in the light of real-world epidemiology. Gastrointest Disord. 2018;1:129–146.
- Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–1880.
- Yzet C, Dupas J-L, Fumery M. Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease. Am J Gastroenterol. 2016;111:748–749.
- Høivik ML, Moum B, Solberg IC, et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut. 2013;62:368–375.
- Eriksson C, Marsal J, Bergemalm D, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017;52:722–729.
- Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther. 2001;15:1515–1525.
- Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15:25–36.e27.